E-Book Overview
This important and exciting work brings together a high-calibre group of experts to discuss the practical application of genomic information to the development of drugs. Recent technological advances have led to a rapid acceleration in our ability to gather genetic data. The complete genetic sequences are now known for several organisms and accelerated programmes are in place for sequencing many other genomes, including human. The speed with which complete sequencing can be accomplished will continue to increase as new technologies come online. In principle, the scope for developing new diagnostic techniques and drugs is now greater than at any time in human history, but the pathway from genetic information to usable drug is a long and complex one.This major book covers such subjects as the current state of the art in squencing technology, the applications of these new technologies to sequencing the genomes of various organisms, and the challenge of proteomics. Additional contributions deal with legal and ethical implications of the new uses of genetic data, and functional genomics from the point of view of the pharmaceutical industry.
E-Book Content
Novartis 229: From Genome toTherapy: Integrating NewTechnologies with Drug Development. Copyright & 2000 John Wiley & Sons Ltd Print ISBN 0-471-62744-5 eISBN 0-470-84664-X
FROM GENOME TO THERAPY:
INTEGRATING NEW TECHNOLOGIES WITH DRUG DEVELOPMENT
Novartis 229: From Genome toTherapy: Integrating NewTechnologies with Drug Development. Copyright & 2000 John Wiley & Sons Ltd Print ISBN 0-471-62744-5 eISBN 0-470-84664-X
The Novartis Foundation is an international scienti¢c and educational charity (UK Registered Charity No. 313574). Known until September 1997 as the Ciba Foundation, it was established in 1947 by the CIBA company of Basle, which merged with Sandoz in 1996, to form Novartis. The Foun